Burgundy Cancer Institute Pioneers Personalized Radiotherapy with Novel Blood Test
Auxerre, France – The Burgundy Cancer Institute (ICB) is now the first healthcare provider in Burgundy-Franche-Comté to systematically offer a groundbreaking blood test designed to personalize radiotherapy treatment for breast and prostate cancer patients. The innovation,developed by Novagray and validated by the French Société de Radiotherapie oncologique,promises to refine treatment plans by identifying individual patient sensitivity to radiation.
this advancement marks a notable step towards precision oncology, allowing clinicians to tailor treatment intensity based on a patient’s biological response. “We give visibility in the long term,” explains Clémence Franc, co-founder and CEO of Novagray. “Some patients discover that they are particularly sensitive and benefit from personalized follow-up.Others, in contrast, know that they can tolerate a standard treatment without over-risk. It’s reassuring for everyone.”
The ICB is uniquely positioned as a regional leader in innovative cancer care, absorbing the cost of the test – currently not reimbursed by French Social Security – to ensure accessibility for its patients. This commitment extends to a broader strategy encompassing oncocardiology, respiratory blocking techniques to protect heart health during breast cancer treatment, and the growth of advanced consultations across nine partner establishments in the region.
“Our philosophy is simple: the patient must be co-actor of his treatment,” emphasizes Dr. Lépinoy. “And innovation has only value if it really improves his quality of life,during and after care.“
By integrating this test into its standard practice, the ICB signals a shift towards personalized medicine as a tangible reality, offering patients reduced uncertainty, increased safety, and a greater sense of security regarding potential long-term complications. The simple blood draw represents a perhaps profound impact on patient outcomes and well-being.
